Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) EBIT (2022 - 2025)

Century Therapeutics (IPSC) has disclosed EBIT for 4 consecutive years, with -$36.1 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT fell 3.84% to -$36.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$33.9 million, a 76.56% increase, with the full-year FY2024 number at -$138.1 million, up 5.74% from a year prior.
  • EBIT was -$36.1 million for Q3 2025 at Century Therapeutics, down from -$34.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $74.2 million in Q1 2025 to a low of -$43.8 million in Q4 2023.
  • A 4-year average of -$27.7 million and a median of -$34.8 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 31.39% in 2023, then soared 336.92% in 2025.
  • Century Therapeutics' EBIT stood at -$33.3 million in 2022, then plummeted by 31.39% to -$43.8 million in 2023, then increased by 14.8% to -$37.3 million in 2024, then rose by 3.11% to -$36.1 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's EBIT are -$36.1 million (Q3 2025), -$34.7 million (Q2 2025), and $74.2 million (Q1 2025).